Eastwood Bio-Medical Canada Overview
Get informed when a big investor buys or sells
+ Follow42.45%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for EBM.V is 42.45%. That is above the sector sector average of 11.64%. Investors often review this figure alongside Eastwood Bio-Medical Canada's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, EBM.V currently prints 42.45% for ROE, while the sector average sits near 11.64%. That is roughly 264.8% above the sector mean. Large gaps often invite a closer look at Eastwood Bio-Medical Canada's growth, margins, and balance sheet.
Return on Equity shows how effectively Eastwood Bio-Medical Canada converts resources into returns. At 42.45%, EBM.V may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting EBM.V's ROE (42.45%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
